ISLAMABAD – In a major breakthrough for HIV prevention, the World Health Organization (WHO) has officially recommended lenacapavir, a long-acting injection given just twice a year, to stop the spread of HIV.
The drug, developed by US-based company Gilead Sciences, has shown over 99% effectiveness in clinical trials. Health experts are calling it the most powerful HIV prevention method yet—especially helpful for those who struggle with daily pills.
Speaking at the International AIDS Conference in Rwanda, WHO officials said the new injection could become a game-changer in the global fight against HIV, especially in countries where the disease remains a serious threat.
Plans are underway to roll out lenacapavir across low- and middle-income countries, with up to 2 million people expected to receive it in the next three years through global partnerships.
The injection is seen as the closest option to an HIV vaccine, and health authorities are urging governments to make it available to high-risk groups as soon as possible.
This story has been reported by PakTribune. All rights reserved.